Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Becker

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Nature|April 21, 2022
Global seasonal forecasts of marine heatwavesMichael G Jacox, Michael A Alexander, Dillon Amaya, et al.
Inflammatory Bowel Diseases|May 23, 2018
Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-sMarie-Theres Binder, Emily Becker, Maximilian Wiendl, et al.
Journal of the American Academy of Dermatology|January 24, 2024
Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trialLoretta Fiorillo, Emily Becker, Raul de Lucas, et al.
Child Maltreatment|December 15, 2023
Clinical Consultation During a Trauma-Focused Cognitive Behavioral Therapy Community-Based Learning Collaborative: Examination of Consultation Content, Consultative Strategies, and Provider EngagementGrace S Woodard, Ashley Smith Cheng, Dominique A Phillips, et al.
Therapeutic Advances in Gastroenterology|December 6, 2021
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitisMichaela Melde, Tanja M Müller, Ines Schneider, et al.
BMC Gastroenterology|April 16, 2020
Baseline levels of dynamic CD4<sup>+</sup> T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort studyClarissa Allner, Michaela Melde, Emily Becker, et al.
Behaviour Research and Therapy|September 3, 2017
The relationship between consumer, clinician, and organizational characteristics and use of evidence-based and non-evidence-based therapy strategies in a public mental health systemRinad Beidas, Laura Skriner, Danielle Adams, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|October 22, 2022
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel diseaseInes Schneider, Clarissa Allner, Laura Mühl, et al.
Clinical and Translational Medicine|April 8, 2023
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healingKatrin Sommer, Karin Heidbreder, Lucas Kreiss, et al.
Frontiers in Pharmacology|February 19, 2019
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel DiseaseCharlotte Lichnog, Sha Klabunde, Emily Becker, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Nature|April 21, 2022
Global seasonal forecasts of marine heatwavesMichael G Jacox, Michael A Alexander, Dillon Amaya, et al.
Inflammatory Bowel Diseases|May 23, 2018
Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-sMarie-Theres Binder, Emily Becker, Maximilian Wiendl, et al.
Journal of the American Academy of Dermatology|January 24, 2024
Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trialLoretta Fiorillo, Emily Becker, Raul de Lucas, et al.
Child Maltreatment|December 15, 2023
Clinical Consultation During a Trauma-Focused Cognitive Behavioral Therapy Community-Based Learning Collaborative: Examination of Consultation Content, Consultative Strategies, and Provider EngagementGrace S Woodard, Ashley Smith Cheng, Dominique A Phillips, et al.
Therapeutic Advances in Gastroenterology|December 6, 2021
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitisMichaela Melde, Tanja M Müller, Ines Schneider, et al.
BMC Gastroenterology|April 16, 2020
Baseline levels of dynamic CD4<sup>+</sup> T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort studyClarissa Allner, Michaela Melde, Emily Becker, et al.
Behaviour Research and Therapy|September 3, 2017
The relationship between consumer, clinician, and organizational characteristics and use of evidence-based and non-evidence-based therapy strategies in a public mental health systemRinad Beidas, Laura Skriner, Danielle Adams, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|October 22, 2022
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel diseaseInes Schneider, Clarissa Allner, Laura Mühl, et al.
Clinical and Translational Medicine|April 8, 2023
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healingKatrin Sommer, Karin Heidbreder, Lucas Kreiss, et al.
Frontiers in Pharmacology|February 19, 2019
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel DiseaseCharlotte Lichnog, Sha Klabunde, Emily Becker, et al.
Pageof 5